CMC Biologics Expands Its Production Facility and Rebrands Its Corporate Identity
By Cmc Biologics, PRNETuesday, June 21, 2011
COPENHAGEN, Denmark and SEATTLE, Washington, June 22, 2011 -
CMC Biologics today announced that it is in the final stages of
expanding its stainless steel biopharmaceutical production facility
at its Bothell campus and it has rebranded its corporate identity
with an exciting new logo and a compelling tagline. These recent
changes are part of the continued growth of the Company.
(Logo:
The Company is completing the expansion of its state-of-the-art
stainless steel biopharmaceutical manufacturing facility, known as
PF2, to increase capacity and support commercial manufacturing with
the addition of a 3,000 liter bioreactor train. The modification of
PF2 is part of a staged major expansion plan that started with the
construction of a multipurpose single-use facility (PF1), completed
in 2010, and is expected to include the build-out of a facility to
house two 5,000 liter commercial-ready manufacturing lines.
“We measure our success by the results we deliver to our
customers,” said Gustavo F. Mahler, Ph.D., Global Chief Operations
Officer of CMC Biologics. “The expansion of PF2 will add
significant production capacity to CMC Biologics’ existing
facilities to accommodate growing demand for cGMP manufacture of
biopharmaceuticals.”
“The rebranding, which coincides with the Company’s tenth
anniversary, isn’t just about a new logo. It’s about our reputation
and image in the market,” noted Claes Glassell, CEO of CMC
Biologics. “The new tagline ‘Right. On Time.’ conveys our
commitment to our customers.”
About CMC Biologics
CMC Biologics (
dedicated contract biopharmaceutical manufacturing and development
organization with facilities in Copenhagen, Denmark and Seattle,
Washington, USA. CMC Biologics specializes in custom services for
scale up and cGMP manufacture of protein-based therapeutics for
preclinical, clinical trials, and in-market production. The
Company’s fully integrated services includes cell line development
using its proprietary CHEF1® system, process and formulation
development, and comprehensive analytical testing. CMC Biologics
has fully segregated microbial fermentation and mammalian cell
culture suites and offers stirred tank and perfusion production
processes.
Leah Grant of CMC Biologics, +1-206-660-4003, lgrant at cmcbio.com
Tags: Cmc Biologics, Copenhagen, denmark, Denmark And Seattle, June 22, Washington
